Literature DB >> 32146835

Numb negatively regulates the epithelial-to-mesenchymal transition in colorectal cancer through the Wnt signaling pathway.

Chi Cheng1, Zhenfeng Huang1, Ruiyao Zhou1, Huimin An2, Gaojian Cao1, Jun Ye3, Chaolin Huang4, Daoyi Wu1.   

Abstract

Colorectal cancer (CRC) is one of the most common malignant tumors and is associated with a high mortality rate due to the lack of specific biomarkers available for early diagnosis, targeted therapies, and prognostic surveillance. In the present study, we investigated the function of Numb and its underlying mechanism in CRC. Immunohistochemical staining and clinicopathological analysis were used to assess the expression of Numb and its clinical significance in patients with CRC. Quantitative real-time polymerase chain reaction, cell proliferation, Western blot, wound healing, Transwell, and TOP/FOP flash reporter assays were used to investigate the function of Numb and its underlying mechanism in CRC. Numb expression was downregulated and negatively correlated with the depth of invasion, tumor size, metastasis, TNM stage, and epithelial-to-mesenchymal transition (EMT) markers in CRC specimens. Numb negatively regulates the EMT, proliferation, invasion, migration, and the Wnt signaling pathway in vitro, as well as tumor growth and metastasis in vivo. Furthermore, activation of the Wnt signaling pathway by Wnt-3A negated the effect of Numb overexpression, whereas inhibition of the Wnt signaling pathway by IWR-1 impaired the effect of the Numb knockdown on the EMT. We concluded that Numb downregulation is a common event in patients with CRC and is closely correlated with cancer progression and a poor prognosis. Numb functions as a tumor suppressor in CRC, and its tumor suppressor function is mediated by negative regulation of the EMT through the Wnt signaling pathway.NEW & NOTEWORTHY We investigate the function of Numb and its underlying mechanism in colorectal cancer through quantitative real-time polymerase chain reaction, cell proliferation, Western blot, wound healing, Transwell, and TOP/FOP flash reporter assays. We conclude that Numb can negatively regulate the epithelial-to-mesenchymal transition through the Wnt signaling pathway to inhibit the development of colorectal cancer.

Entities:  

Keywords:  Numb; Wnt signaling pathway; cancer stem cells; epithelial-to-mesenchymal transition

Year:  2020        PMID: 32146835     DOI: 10.1152/ajpgi.00178.2019

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  5 in total

1.  Numb exon 9 inclusion regulates Integrinβ5 surface expression and promotes breast cancer metastasis.

Authors:  Yangjing Zhang; Sascha E Dho; Kamal Othman; Craig D Simpson; Jessica Lapierre; Andrew Bondoc; C Jane McGlade
Journal:  Oncogene       Date:  2022-02-18       Impact factor: 8.756

2.  NUMB facilitates autophagy initiation through targeting SCFβ-TrCP2 complex.

Authors:  Hao Li; Shuangshuang Shu; Miaomiao Zhou; Ying Chen; An Xiao; Yuanyuan Ma; Fengxin Zhu; Zheng Hu; Jing Nie
Journal:  Cell Death Differ       Date:  2022-01-11       Impact factor: 12.067

Review 3.  Association of the Epithelial-Mesenchymal Transition (EMT) with Cisplatin Resistance.

Authors:  Milad Ashrafizadeh; Ali Zarrabi; Kiavash Hushmandi; Mahshad Kalantari; Reza Mohammadinejad; Tahereh Javaheri; Gautam Sethi
Journal:  Int J Mol Sci       Date:  2020-06-03       Impact factor: 5.923

4.  Differential Expression Analysis Revealing CLCA1 to Be a Prognostic and Diagnostic Biomarker for Colorectal Cancer.

Authors:  Fang-Ze Wei; Shi-Wen Mei; Zhi-Jie Wang; Jia-Nan Chen; Hai-Yu Shen; Fu-Qiang Zhao; Juan Li; Zheng Liu; Qian Liu
Journal:  Front Oncol       Date:  2020-10-28       Impact factor: 6.244

5.  Numb-PRRL promotes TGF-β1- and EGF-induced epithelial-to-mesenchymal transition in pancreatic cancer.

Authors:  Weiwei Sheng; Jingtong Tang; Rongxian Cao; Xiaoyang Shi; Yuteng Ma; Ming Dong
Journal:  Cell Death Dis       Date:  2022-02-23       Impact factor: 8.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.